Psychedelics
May 14, 2026
Joseph T. la Torre, Jade Gallo, Matteo Buonaroti et al.
This paper presents qualitative data reported by individuals with histories of psychotic symptoms and experiences who engaged in naturalistic psychedelic use compiled as a case series. Through detailed first-person narratives, we explore how both classic and non-classic psychedelic experiences were subjectively experienced and integrated by individuals in this population, which is usually...
Schizophrenia Research
March 13, 2026
Michel Sabé, Paul Grof, Nathan Sackett et al.
1 citation
Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs)....
Journal of Psychedelic Studies
July 31, 2024
Joseph T. la Torre, Jade Gallo, Mehdi Mahammadli et al.
6 citations
Individuals with a history of psychotic experiences and disorders such as schizophrenia, and mood disorders with psychotic features tend to be excluded from psychedelic-assisted therapy research and treatment programs, despite minimal research demonstrating heightened risk of adverse effects for this group. Participants (n = 100) were asked to complete an online, retrospective survey that asked...
Journal of Psychedelic Studies
May 6, 2024
Mark Cornfield, S. Mcbride, Joseph T. la Torre et al.
6 citations
This study contributes to the understanding of the efficacy, safety, and experience of ketamine-assisted therapy. The paper documents how individuals describe the effects of a protocolized and personalized use of ketamine (‘the relational dose’) in the context of group couples therapy based on Imago Relationship Therapy (IRT). Little is known about simultaneously administering ketamine to both...